Lumicitabine: Clinical Trials

3 terminated, 2 completed, 1 withdrawn. 4 Phase 2, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	4	Terminated 2, Completed 1, Withdrawn 1
Phase 1	2	Completed 1, Terminated 1

Follow Lumicitabine: new trials by email Literature Review of Lumicitabine trials Research Report on Lumicitabine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus Lumicitabine, Placebo - Metapneumovirus	Phase 2	Withdrawn	Janssen Research & Development, LLC		2018-11-05	2018-11-15
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants Lumicitabine, Lansoprazole, Ranitidine - Healthy	Phase 1	Terminated	Janssen Research & Development, LLC	18	2018-03-06	2018-07-23
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants Lumicitabine, Piperacillin/Tazobactam - Healthy	Phase 1	Completed	Janssen Research & Development, LLC	18	2018-02-09	2018-06-07
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection Lumicitabine, Placebo - Respiratory Syncytial Virus Infections	Phase 2	Completed	Janssen Research & Development, LLC	7	2018-01-05	2021-04-13
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus Lumicitabine, Placebo - Respiratory Syncytial Viruses	Phase 2	Terminated	Janssen Research & Development, LLC	7	2017-11-24	2019-12-23
Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus lumicitabine, Placebo - Respiratory Syncytial Viruses	Phase 2	Terminated	Janssen Research & Development, LLC	49	2016-10-25	2019-12-24

Conditions studied

Respiratory Syncytial Virus Infections (1)

Sponsors

Janssen Research & Development, LLC (6)

Countries

Belgium (4)  ·  Japan (4)  ·  Poland (3)  ·  United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Brazil (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  France (2)  ·  Malaysia (2)  ·  Netherlands (2)  ·  South Korea (2)  ·  Spain (2)  ·  Sweden (2)

Results publications

PMID 37467213

NIH funding

2017 (4), 2016 (2)